LYTIR

Company · SCTX

Scribe Therapeutics Inc.

Name as listed on its exchange; filed with the SEC as Scribe Therapeutics, Inc.

Nasdaq's symbol directory lists SCTX on Nasdaq as “Scribe Therapeutics Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 6 occasions ($56.3M); 4 filings by holders of 5% or more.

All insider filings at the SEC

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Behzad Aghazadeh bought on 2 days latest Jul 28, 2026 bought $36.3M
  2. ORBIMED ADVISORS LLC bought on 1 day latest Jul 27, 2026 bought $15.0M
  3. AH Bio Fund II, L.P. bought on 1 day latest Jul 27, 2026 bought $5.0M
  4. Lucas Svetlana, Chief Business Officer bought on 1 day latest Jul 23, 2026 bought $45K
  5. Parrot David, Chief Financial Officer bought on 1 day latest Jul 23, 2026 bought $40K
Every trade (6)
  1. BUYBehzad Aghazadeh bought Jul 28, 2026 7,905 shares filing $144K
  2. BUYORBIMED ADVISORS LLC bought Jul 27, 2026 1,000,000 shares filing $15.0M
  3. BUYAH Bio Fund II, L.P. bought Jul 27, 2026 333,333 shares filing $5.0M
  4. BUYBehzad Aghazadeh bought Jul 24, 2026 2,383,333 shares 2 legs combined filing $36.1M
  5. BUYLucas Svetlana, Chief Business Officer bought Jul 23, 2026 3,000 shares filing $45K
  6. BUYParrot David, Chief Financial Officer bought Jul 23, 2026 2,666 shares 2 legs combined filing $40K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. RA Capital Management, L.P. filed Aug 3, 2026 Schedule 13G passive filing 9.6%
  2. Avoro Capital Advisors LLC filed Jul 30, 2026 Schedule 13D may seek influence 2,598,973 shares filing 13.78%
  3. ELI LILLY & Co filed Jul 30, 2026 Schedule 13D may seek influence 1,388,161 shares filing 7.3%
  4. ORBIMED ADVISORS LLC filed Jul 29, 2026 Schedule 13D may seek influence 1,348,825 shares filing 7.2%

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.